BioCryst Pharmaceuticals (BCRX) said Tuesday that Chief Financial Officer Anthony Doyle intends to resign from the company, effective April 9.
BioCryst said Doyle's resignation is not the result of any disagreement with the company on any matter relating to operations, policies, or practices.
The company said it is now searching for a new CFO and that Doyle will remain in his role through April 9 to ensure a smooth transition.
BioCryst shares were down 3.6% in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.